May 15, 2018 / 12:14 PM / 6 months ago

BRIEF-Novan Provides Update On SB414 Inflammatory Skin Disease Development Program

May 15 (Reuters) - Novan Inc:

* NOVAN PROVIDES UPDATE ON SB414 INFLAMMATORY SKIN DISEASE DEVELOPMENT PROGRAM

* NOVAN INC - SB414 - NITRIC OXIDE-RELEASING CREAM - SAFE AND WELL-TOLERATED IN PSORIASIS PHASE 1B TRIAL

* NOVAN - ATOPIC DERMATITIS-PHASE 1B CLINICAL TRIAL FULLY ENROLLED, CO CONTINUES TO TARGET RECEIPT OF INITIAL TOPLINE RESULTS IN Q3 2018 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below